Princess Margaret Cancer Centre, Drug Development Program, University Health Network, Toronto, Canada.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Oncologist. 2019 Apr;24(4):e146-e148. doi: 10.1634/theoncologist.2018-0332. Epub 2019 Feb 6.
The patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) complements capture of symptomatic adverse events (AEs) by clinicians. Previous trials have typically used a limited subset of relevant symptomatic AEs to reduce patient burden. We aimed to determine the feasibility of administering all 80 AEs included in the PRO-CTCAE library by approaching consecutive patients enrolled in a large academic phase I program at three points in time. Here, we report a preplanned analysis after enrolling the first 20 patients. All items were answered on 51 of 56 potential visits (adherence 91%). Three (5%) additional PRO-CTCAE assessments were partially completed, and two (4%) were missed because of conflicting appointments. No patient withdrew consent or chose not to complete the assessments once enrolled on study. Future trials of experimental drugs that incorporate the PRO-CTCAE should consider using this unselected approach to identify adverse events more completely.
患者报告结局版常见不良事件术语标准(PRO-CTCAE)补充了临床医生对症状不良事件(AE)的捕捉。之前的试验通常使用有限的一组相关症状 AE 来减轻患者负担。我们旨在通过在三个时间点接近在三个大型学术 I 期计划中入组的连续患者,确定管理 PRO-CTCAE 库中包含的所有 80 个 AE 的可行性。在这里,我们报告了在入组前 20 名患者后的预先计划分析。在 56 个潜在访问中的 51 个(依从性 91%)回答了所有项目。由于预约冲突,有 3 项(5%)额外的 PRO-CTCAE 评估部分完成,有 2 项(4%)遗漏。一旦入组研究,没有患者撤回同意或选择不完成评估。未来的实验性药物试验如果纳入 PRO-CTCAE,应考虑使用这种未经选择的方法更全面地识别不良事件。